Delivery Order SPE2DB20D3505-SPE2DB25FU8M3

Award Date 6/20/25
Potential Completion Date 6/23/25
Potential Value $2.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,020.88, is a delivery order for the medical product "ADBRY 300 MG/2 ML AUTOINJECTOR 2ML". The contract has an ultimate completion date of April 10, 2025 and is a firm fixed-price contract. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,150.03, is for the delivery of ADBRY 300 MG/2 ML AUTOINJECTOR 2ML, a medical product. The contract has an ultimate completion date of April 4, 2025 and is a firm fixed-price delivery order. This award is part of AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,020.88, is for the delivery of a specific pharmaceutical product, ADBRY 300 MG/2 ML AUTOINJECTOR 2ML. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 11, 2025. The contract is not set aside for any specific business category. Amerisourcebergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The contract is for the delivery of ADBRY 300 MG/2 ML AUTOINJECTOR 2ML, a medical product, with a ceiling value of $1,020.88. The contract has an ultimate completion date of June 10, 2025 and is a Firm Fixed Price Delivery Order. Amerisourcebergen Drug Corp holds a significant...
The U.S. Defense Logistics Agency (DLA) awarded a $9,201.62 firm-fixed price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract is for the supply of ADBRY 150 MG/ML SYRINGEML, a medical product, with a completion date of April 18, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical to provide a broad range...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,041.76 firm fixed-price contract is for the supply of ADBRY 150 MG/ML syringes and has an ultimate completion date of February 4, 2025. Amerisourcebergen holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves as a primary vehicle for...
This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $3,028.98 contract is for the delivery of ADBRY 150 MG/ML SYRINGEML pharmaceutical products to support military treatment programs and facilities. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ADBRY 150 mg/ml syringes, a medical product, with a ceiling value of $40,396.08 and a period of performance extending to May 21, 2025. The contract is a Firm Fixed Price type and is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a significant...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $541,330.31 contract has an ultimate completion date of December 20, 2024 and covers the delivery of a range of pharmaceutical products and medical supplies, including medications across multiple therapeutic areas such as diabetes, neurology, pain management, and antibiotics. Amerisourcebergen Drug Corp...
This is a $12,356.85 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of April 1, 2025 and does not have a set-aside designation. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle for providing a...
  • SPE2DB20D3505
    Indefinite Delivery Contract
  • SPE2DB20D3505-SPE2DB25FU8M3
    Delivery Order

This is a $2,337.32 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of ADBRY 300 MG/2 ML AUTOINJECTOR 2ML, a medical product, with a completion date of June 23, 2025. The contract is not set-aside.

AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This delivery order is likely part of the broader IDC, enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.

Generated 9/19/25, 10:51 AM